Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BRN 6848330; CCRIS 6729; DM 9384; DMPPA; DN-9384; DZL-221; HL-0812; HPI-001; Motiva; Translon

Latest Information Update: 27 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Neuren Pharmaceuticals
  • Class Acetamides; Neuroprotectants; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Calcium channel agonists; GABA receptor agonists; Nicotinic receptor agonists; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy
  • Discontinued Dementia; Major depressive disorder

Most Recent Events

  • 15 Mar 2011 Phase-II development is ongoing in US, Australia and Canada for Depression in post-stroke patients
  • 08 Jun 2010 Clinical development is ongoing
  • 12 Mar 2008 Phase-II clinical trials in Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top